43 results
8-K
EX-99.1
IKT
Inhibikase Therapeutics Inc
20 May 24
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant
8:55am
, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases. Its
8-K
EX-99.1
IKT
Inhibikase Therapeutics Inc
30 Apr 24
Regulation FD Disclosure
8:17am
OF TARGETING? antibody or Clearance of pathological plaque unknown dis-aggregator targets plaque NOT restorative outside affected neurons mechanistic … inhibitors Does clear pathological plaques like risvodetinib CAN BE restorative target plaque inside affected neurons 1 Ø Risvodetinib targets
8-K
EX-99.1
98z97ru
18 Apr 24
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
9:46pm
8-K
EX-99.1
emu2ehnrs1jm0
7 Feb 24
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA
7:59am
424B5
i8c1ci3m1eyro 3sig8
1 Feb 24
Prospectus supplement for primary offering
4:49pm
8-K
EX-10.1
uucbp3jdmoywkiama07k
1 Feb 24
Entry into a Material Definitive Agreement
4:09pm
8-K
EX-99.1
jmg24 x4ggxm2lxqj
16 Jan 24
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
4:31pm
8-K
EX-99.1
lo67kx6bwx
20 Sep 23
Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity
11:23am
8-K
EX-99.2
fx6izktx0r8z
17 Jul 23
Other Events
5:29pm
8-K
EX-99.1
aijjm4g76e56u ydtb
29 Jun 23
Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split
12:15pm
424B3
lopuiz dvwie1h8e69y
4 Apr 23
Prospectus supplement
4:57pm